Beova Special Precautions

Precautions Concerning Indications: Prior to use of this product, clinical symptoms of patients should be confirmed with an appropriate interview, and diagnosis by exclusion of some other diseases with similar symptoms, including urinary tract infection, urinary calculus, and lower urinary-tract neoplasm such as bladder cancer and prostate cancer, should be made by performing appropriate examinations such as urinalysis. In addition, special examinations should be considered to conduct, if necessary.
For patients with lower urinary-tract obstructive disease, including benign prostatic hyperplasia, treatment for these diseases should be prioritized.
Precautions Concerning Patients with Specific Backgrounds: Patients with Complication or History of Diseases: Patients with severe cardiac disease: Symptoms may be aggravated due to heart rate increased.
Patients with Hepatic Impairment: Patients with advanced hepatic impairment: Blood concentration of Vibegron may increase [See Pharmacology: Pharmacokinetics under Actions].
Precautions for Co-administration (This drug should be administered with caution when co-administered with the following): See Table 10.

Click on icon to see table/diagram/image

Precautions Concerning Use: Precautions Concerning the Dispensing of the Drug: Patients should be instructed to press the tablet out of a press-through package (PTP) before administration. The sharp corner of swallowed PTP sheet may puncture the esophageal mucosa, resulting in serious complications such as mediastinitis.
Effects on ability to drive and use machines: Not applicable.
Use in Children: No clinical studies in children have been conducted.
Use in the Elderly: Beova should be administered with care while monitoring the condition of the patient. The physiological functions are generally reduced in the elderly [See Pharmacology: Pharmacokinetics under Actions].